HEADER ONCOPROTEIN 24-JUN-08 3DKF TITLE STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR TITLE 2 SGX-523 COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEPATOCYTE GROWTH FACTOR RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: HGF RECEPTOR, HGF/SF RECEPTOR, PROTO-ONCOGENE C-MET, SCATTER COMPND 5 FACTOR RECEPTOR, SF RECEPTOR, TYROSINE-PROTEIN KINASE MET; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: MET, HCG_38705, TCAG7.66; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 9 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS DRUG DISCOVERY, C-MET KINASE, FRAGMENT BASED, MEMBRANE, RECEPTOR, KEYWDS 2 TRANSMEMBRANE, ONCOPROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR J.HENDLE REVDAT 6 21-FEB-24 3DKF 1 REMARK REVDAT 5 10-FEB-21 3DKF 1 JRNL REMARK SEQADV REVDAT 4 22-APR-15 3DKF 1 COMPND DBREF REMARK TITLE REVDAT 4 2 1 VERSN REVDAT 3 19-JAN-10 3DKF 1 JRNL REVDAT 2 06-OCT-09 3DKF 1 JRNL REVDAT 1 07-JUL-09 3DKF 0 JRNL AUTH S.G.BUCHANAN,J.HENDLE,P.S.LEE,C.R.SMITH,P.Y.BOUNAUD, JRNL AUTH 2 K.A.JESSEN,C.M.TANG,N.H.HUSER,J.D.FELCE,K.J.FRONING, JRNL AUTH 3 M.C.PETERMAN,B.E.AUBOL,S.F.GESSERT,J.M.SAUDER,K.D.SCHWINN, JRNL AUTH 4 M.RUSSELL,I.A.ROONEY,J.ADAMS,B.C.LEON,T.H.DO,J.M.BLANEY, JRNL AUTH 5 P.A.SPRENGELER,D.A.THOMPSON,L.SMYTH,L.A.PELLETIER,S.ATWELL, JRNL AUTH 6 K.HOLME,S.R.WASSERMAN,S.EMTAGE,S.K.BURLEY,S.H.REICH JRNL TITL SGX523 IS AN EXQUISITELY SELECTIVE, ATP-COMPETITIVE JRNL TITL 2 INHIBITOR OF THE MET RECEPTOR TYROSINE KINASE WITH ANTITUMOR JRNL TITL 3 ACTIVITY IN VIVO. JRNL REF MOL.CANCER THER. V. 8 3181 2009 JRNL REFN ISSN 1535-7163 JRNL PMID 19934279 JRNL DOI 10.1158/1535-7163.MCT-09-0477 REMARK 2 REMARK 2 RESOLUTION. 1.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 34.99 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 24264 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING + TEST SET) : NULL REMARK 3 R VALUE (WORKING SET) : 0.191 REMARK 3 FREE R VALUE : 0.233 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2263 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 27 REMARK 3 SOLVENT ATOMS : 213 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.78 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): NULL REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): NULL REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3DKF COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 08-JUL-08. REMARK 100 THE DEPOSITION ID IS D_1000048148. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 19-JAN-07 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 31-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97969 REMARK 200 MONOCHROMATOR : DIAMOND REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MAR CCD 165 MM REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : SCALA 3.2.5 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24264 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800 REMARK 200 RESOLUTION RANGE LOW (A) : 34.986 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 79.7 REMARK 200 DATA REDUNDANCY : 4.300 REMARK 200 R MERGE (I) : 0.05500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 44.82 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.23 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% ISOPROPANOL, 200 MM AMMONIUM REMARK 280 ACETATE, 100 MM TRIS, PH 7.5, VAPOR DIFFUSION, TEMPERATURE 292K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 21.54450 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 79.24100 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 23.33950 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 79.24100 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 21.54450 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 23.33950 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 1046 REMARK 465 SER A 1047 REMARK 465 LEU A 1048 REMARK 465 ASN A 1049 REMARK 465 LEU A 1098 REMARK 465 ASP A 1099 REMARK 465 ASN A 1100 REMARK 465 ASP A 1101 REMARK 465 GLY A 1102 REMARK 465 ASP A 1231 REMARK 465 LYS A 1232 REMARK 465 GLU A 1233 REMARK 465 PHE A 1234 REMARK 465 ASP A 1235 REMARK 465 SER A 1236 REMARK 465 VAL A 1237 REMARK 465 HIS A 1238 REMARK 465 ASN A 1239 REMARK 465 LYS A 1240 REMARK 465 THR A 1241 REMARK 465 GLY A 1242 REMARK 465 ALA A 1243 REMARK 465 GLY A 1362 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU A1058 CG CD1 CD2 REMARK 470 LEU A1062 CG CD1 CD2 REMARK 470 VAL A1063 CG1 CG2 REMARK 470 GLN A1064 CG CD OE1 NE2 REMARK 470 GLN A1067 CG CD OE1 NE2 REMARK 470 ASN A1081 CG OD1 ND2 REMARK 470 GLU A1082 CG CD OE1 OE2 REMARK 470 VAL A1083 CG1 CG2 REMARK 470 ARG A1086 CG CD NE CZ NH1 NH2 REMARK 470 LYS A1103 CG CD CE NZ REMARK 470 LYS A1104 CG CD CE NZ REMARK 470 GLU A1120 CG CD OE1 OE2 REMARK 470 GLN A1123 CG CD OE1 NE2 REMARK 470 GLU A1127 CG CD OE1 OE2 REMARK 470 ARG A1148 CG CD NE CZ NH1 NH2 REMARK 470 SER A1149 OG REMARK 470 LYS A1244 CG CD CE NZ REMARK 470 LYS A1259 CG CD CE NZ REMARK 470 PHE A1290 CG CD1 CD2 CE1 CE2 CZ REMARK 470 ASP A1291 CG OD1 OD2 REMARK 470 LYS A1360 CG CD CE NZ REMARK 470 GLU A1361 CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A1203 -17.26 75.69 REMARK 500 ALA A1221 -153.90 -127.05 REMARK 500 ASP A1291 15.37 -141.97 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 2 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SX8 A 1 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3DKC RELATED DB: PDB REMARK 900 STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP REMARK 900 RELATED ID: 3DKG RELATED DB: PDB REMARK 900 STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX REMARK 900 WITH INHIBITOR SGX-523 DBREF 3DKF A 1049 1360 UNP P08581 MET_HUMAN 1049 1360 SEQADV 3DKF GLY A 1046 UNP P08581 EXPRESSION TAG SEQADV 3DKF SER A 1047 UNP P08581 EXPRESSION TAG SEQADV 3DKF LEU A 1048 UNP P08581 EXPRESSION TAG SEQADV 3DKF PHE A 1194 UNP P08581 TYR 1194 ENGINEERED MUTATION SEQADV 3DKF PHE A 1234 UNP P08581 TYR 1234 ENGINEERED MUTATION SEQADV 3DKF ASP A 1235 UNP P08581 TYR 1235 ENGINEERED MUTATION SEQADV 3DKF GLU A 1361 UNP P08581 EXPRESSION TAG SEQADV 3DKF GLY A 1362 UNP P08581 EXPRESSION TAG SEQRES 1 A 317 GLY SER LEU ASN THR VAL HIS ILE ASP LEU SER ALA LEU SEQRES 2 A 317 ASN PRO GLU LEU VAL GLN ALA VAL GLN HIS VAL VAL ILE SEQRES 3 A 317 GLY PRO SER SER LEU ILE VAL HIS PHE ASN GLU VAL ILE SEQRES 4 A 317 GLY ARG GLY HIS PHE GLY CYS VAL TYR HIS GLY THR LEU SEQRES 5 A 317 LEU ASP ASN ASP GLY LYS LYS ILE HIS CYS ALA VAL LYS SEQRES 6 A 317 SER LEU ASN ARG ILE THR ASP ILE GLY GLU VAL SER GLN SEQRES 7 A 317 PHE LEU THR GLU GLY ILE ILE MET LYS ASP PHE SER HIS SEQRES 8 A 317 PRO ASN VAL LEU SER LEU LEU GLY ILE CYS LEU ARG SER SEQRES 9 A 317 GLU GLY SER PRO LEU VAL VAL LEU PRO TYR MET LYS HIS SEQRES 10 A 317 GLY ASP LEU ARG ASN PHE ILE ARG ASN GLU THR HIS ASN SEQRES 11 A 317 PRO THR VAL LYS ASP LEU ILE GLY PHE GLY LEU GLN VAL SEQRES 12 A 317 ALA LYS GLY MET LYS PHE LEU ALA SER LYS LYS PHE VAL SEQRES 13 A 317 HIS ARG ASP LEU ALA ALA ARG ASN CYS MET LEU ASP GLU SEQRES 14 A 317 LYS PHE THR VAL LYS VAL ALA ASP PHE GLY LEU ALA ARG SEQRES 15 A 317 ASP MET TYR ASP LYS GLU PHE ASP SER VAL HIS ASN LYS SEQRES 16 A 317 THR GLY ALA LYS LEU PRO VAL LYS TRP MET ALA LEU GLU SEQRES 17 A 317 SER LEU GLN THR GLN LYS PHE THR THR LYS SER ASP VAL SEQRES 18 A 317 TRP SER PHE GLY VAL LEU LEU TRP GLU LEU MET THR ARG SEQRES 19 A 317 GLY ALA PRO PRO TYR PRO ASP VAL ASN THR PHE ASP ILE SEQRES 20 A 317 THR VAL TYR LEU LEU GLN GLY ARG ARG LEU LEU GLN PRO SEQRES 21 A 317 GLU TYR CYS PRO ASP PRO LEU TYR GLU VAL MET LEU LYS SEQRES 22 A 317 CYS TRP HIS PRO LYS ALA GLU MET ARG PRO SER PHE SER SEQRES 23 A 317 GLU LEU VAL SER ARG ILE SER ALA ILE PHE SER THR PHE SEQRES 24 A 317 ILE GLY GLU HIS TYR VAL HIS VAL ASN ALA THR TYR VAL SEQRES 25 A 317 ASN VAL LYS GLU GLY HET CL A 2 1 HET SX8 A 1 26 HETNAM CL CHLORIDE ION HETNAM SX8 6-{[6-(1-METHYL-1H-PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3- HETNAM 2 SX8 B]PYRIDAZIN-3-YL]SULFANYL}QUINOLINE FORMUL 2 CL CL 1- FORMUL 3 SX8 C18 H13 N7 S FORMUL 4 HOH *213(H2 O) HELIX 1 1 ASP A 1054 LEU A 1058 5 5 HELIX 2 2 ASN A 1059 VAL A 1066 1 8 HELIX 3 3 GLN A 1067 VAL A 1070 5 4 HELIX 4 4 ASP A 1117 ASP A 1133 1 17 HELIX 5 5 ASP A 1164 ASN A 1171 1 8 HELIX 6 6 THR A 1177 LYS A 1198 1 22 HELIX 7 7 ALA A 1206 ARG A 1208 5 3 HELIX 8 8 PHE A 1223 ARG A 1227 5 5 HELIX 9 9 PRO A 1246 MET A 1250 5 5 HELIX 10 10 ALA A 1251 GLN A 1258 1 8 HELIX 11 11 THR A 1261 THR A 1278 1 18 HELIX 12 12 ASN A 1288 PHE A 1290 5 3 HELIX 13 13 ASP A 1291 GLN A 1298 1 8 HELIX 14 14 PRO A 1309 TRP A 1320 1 12 HELIX 15 15 LYS A 1323 ARG A 1327 5 5 HELIX 16 16 SER A 1329 THR A 1343 1 15 SHEET 1 A 5 ILE A1077 GLY A1087 0 SHEET 2 A 5 GLY A1090 LEU A1097 -1 O VAL A1092 N GLY A1085 SHEET 3 A 5 ILE A1105 LEU A1112 -1 O VAL A1109 N TYR A1093 SHEET 4 A 5 SER A1152 PRO A1158 -1 O LEU A1157 N ALA A1108 SHEET 5 A 5 GLY A1144 ARG A1148 -1 N CYS A1146 O LEU A1154 SHEET 1 B 2 CYS A1210 LEU A1212 0 SHEET 2 B 2 VAL A1218 VAL A1220 -1 O LYS A1219 N MET A1211 SITE 1 AC1 4 LYS A1179 GLY A1346 GLU A1347 HIS A1348 SITE 1 AC2 12 ILE A1084 ALA A1108 PRO A1158 TYR A1159 SITE 2 AC2 12 MET A1160 ASP A1164 ARG A1208 MET A1211 SITE 3 AC2 12 ALA A1221 ASP A1222 ALA A1226 TYR A1230 CRYST1 43.089 46.679 158.482 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023208 0.000000 0.000000 0.00000 SCALE2 0.000000 0.021423 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006310 0.00000